Seki Ritsuko 関律子

… Alternative Names

SEKI Ritsuko 関律子

Less

Researcher Number	50446077
Affiliation (Current)	2022: 久留米大学, 医学部, 講師
Affiliation (based on the past Project Information) *help	2011 – 2012: 久留米大学, 医学部, 助教 2010: 久留米大学, 医学部, 研究技術員
Review Section/Research Field	Principal Investigator Human pathology
Keywords	Principal Investigator 細胞 / 組織 / 遺伝子 / 蛋白質 / 細胞・組織

Research Projects
(1 results)
Research Products
(9 results)

Mechanism of the treatment resistance in DLBCL according to Skp2 expression.Principal Investigator
- Principal Investigator
  
  SEKI Ritsuko
- Project Period (FY)
  2010 – 2012
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Human pathology
- Research Institution
  Kurume University

All 2013 2011 2010

All Journal Article Presentation

[Journal Article] Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties.2013
- Author(s)
  Seki R, Yamagishi S, Matsui T,et al
- Journal Title
  
  Biochem Biophys Res Commun.
  
  Volume: 431(4) Pages: 693-697
- DOI
  10.1016/j.bbrc.2013.01.057
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Journal Article] Prognostic significance of S-phase kinase-associated protein 2 and p27kip1in patients with diffuse large B-cell lymphoma: effects of rituximab.2010
- Author(s)
  Ritsuko Seki, Koichi Ohshima, Tomoaki Fujisaki, et al.
- Journal Title
  
  Annals of Oncology
  
  Volume: 21 Pages: 833-841
- DOI
  10.1093/annonc/mdp481
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Journal Article] Prognostic significance of S-phase kinase-associated protein 2 and p27^<kip1> in patients with diffuse large B-cell lymphoma : effects of rituximab.2010
- Author(s)
  Ritsuko Seki
- Journal Title
  
  Annals of Oncology
  
  Volume: 21 Pages: 833-841
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Journal Article] Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B-cell lymphoma in Japan: A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.2010
- Author(s)
  Yuka Takata,Taisuke Kanaji,MasaakiMoroi, Ritsuko Seki, et a
- Journal Title
  
  Int J Hematol.
  
  Volume: 91 Pages: 258-266
- DOI
  10.1007/s12185-009-0475-2
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Journal Article] びまん性大細胞型B細胞性リンパ腫におけるSkp2/p27kip蛋白の予後因子としての有用性2010
- Author(s)
  関律子、大島孝一、岡村孝.
- Journal Title
  
  臨床血液
  
  Volume: 51 Pages: 1741-1743
- NAID
  130004501367
- URL
  https://www.jstage.jst.go.jp/FF01S040Initsourceurl=%2Farticle%2Frinketsu%2F51%2F12%2F51_12_1741%2F_pdf
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Journal Article] Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B-cell lymphoma in Japan : A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.2010
- Author(s)
  Ritsuko Seki
- Journal Title
  
  Int J Hematol.
  
  Volume: 91 Pages: 258-266
- NAID
  10026111459
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22790363
[Presentation] DLBCLにおけるSkp2発現に関するcDNAマイクロアレイ解析2011
- Author(s)
  関律子、荒川文子
- Organizer
  長藤宏司ら第51回日本リンパ網内系学会総会
- Place of Presentation
  福岡国際会議場(福岡)
- Year and Date
  2011-06-30
- Data Source
  KAKENHI-PROJECT-22790363
[Presentation] DLBCLにおけるSkip2発現に関するｃDNAマイクロアレイ解析2011
- Author(s)
  関　律子
- Organizer
  第51回日本リンパ網内系学会総会
- Place of Presentation
  福岡国際会議場（福岡県）
- Data Source
  KAKENHI-PROJECT-22790363
[Presentation] DNA Microarray Analysis in DLBCL Dependent on Skp2 Expression2011
- Author(s)
  Ritsuko Seki
- Organizer
  53nd American Society of Hematology (ASH)
- Place of Presentation
  San Diego Convention Center U.S.A
- Data Source
  KAKENHI-PROJECT-22790363

Seki Ritsuko 関 律子

SEKI Ritsuko 関 律子

Research Projects

Research Products

Mechanism of the treatment resistance in DLBCL according to Skp2 expression.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties.2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prognostic significance of S-phase kinase-associated protein 2 and p27kip1in patients with diffuse large B-cell lymphoma: effects of rituximab.2010

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prognostic significance of S-phase kinase-associated protein 2 and p27^<kip1> in patients with diffuse large B-cell lymphoma : effects of rituximab.2010

Author(s)

Journal Title

Data Source

[Journal Article] Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B-cell lymphoma in Japan: A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.2010

Author(s)

Journal Title

DOI

Data Source

[Journal Article] びまん性大細胞型B細胞性リンパ腫におけるSkp2/p27kip蛋白の予後因子としての有用性2010

Author(s)

Journal Title

NAID

URL

Data Source

[Journal Article] Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B-cell lymphoma in Japan : A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.2010

Author(s)

Journal Title

NAID

Data Source

[Presentation] DLBCLにおけるSkp2発現に関するcDNAマイクロアレイ解析2011

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] DLBCLにおけるSkip2発現に関するｃDNAマイクロアレイ解析2011

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] DNA Microarray Analysis in DLBCL Dependent on Skp2 Expression2011

Author(s)

Organizer

Place of Presentation

Data Source

Seki Ritsuko 関律子

SEKI Ritsuko 関律子